Sight Sciences’ Q4 2025: Margin Resilience and a 2026 Revenue Forecast Emerges for SGHT
Lede
Sight Sciences, SGHT, disclosed fourth quarter 2025 results that look less like a sprint and more like a measured jog: Q4 revenue of $20.4 million, up 7% year over year, and full-year 2025 revenue of $77.4 million, down 3% from 2024. The company kept margins in the neighborhood of prior periods—Q4 gross margin at 87% and full-year gross margin at 86%—even as it trimmed operating expenses by about 13% for the year. With cash and cash equivalents of $92.0 million at December 31, 2025 and Q4 cash usage of $0.4 million, the balance sheet shows a cash cushion that managers can lean on while they push toward future milestones. Notably, the release flags the start of full-year 2026 guidance, hinting at a revenue forecast path to follow—even if the exact numbers aren’t all laid out in this excerpt.
On the earnings side, the filing provides no EPS figure or explicit EPS consensus, so there isn’t an immediate EPS surprise or surprise-to-consensus story to quantify from this release. Market watchers will likely look to the 2026 guidance for a sense of how analysts might form an EPS trajectory, once the company unveils more detail. In the meantime, the press release emphasizes ongoing momentum in Interventional Glaucoma and progress in Interventional Dry Eye after reimbursement milestones, with disciplined cash management as the year wraps.
Key Financial Highlights
- Q4 2025 revenue: $20.4 million, up 7% year over year
- Full-year 2025 revenue: $77.4 million, down 3% from 2024
- Q4 2025 gross margin: 87%; full-year 2025 gross margin: 86% (improvement versus 2024)
- Full-year 2025 operating expense: cohort demonstrates a 13% reduction vs 2024
- Cash and cash equivalents: $92.0 million as of December 31, 2025
- Q4 2025 cash usage: $0.4 million
- Management commentary: renewed growth in Interventional Glaucoma and positive traction in Interventional Dry Eye following reimbursement milestones
- Guidance: Initiation of full-year 2026 financial guidance (revenue forecast forthcoming in complete materials)
Operational and Strategic Takeaways
The spread between the quarterly momentum and the annual decline tells a story of a company recalibrating its growth trajectory. A single quarter can show strength in niche interventional categories, while the full-year number hints at a more conservative revenue profile—perhaps a function of product mix, launch timing, or macro headwinds in elective procedures.
Margin resilience matters here. An 87% gross margin in Q4 and an 86% run-rate for the year suggests the business is extracting more value from its implants, devices, or services relative to cost of goods sold, even as it invests to broaden adoption. The 13% reduction in operating expenses for 2025 reinforces a discipline that investors often reward when growth is uncertain but burn remains controlled.
The cash position—roughly $92 million at year-end and a nominal cash burn in Q4—provides the company room to maneuver as it advances Interventional Glaucoma and tracks reimbursement milestones in Interventional Dry Eye. In a sector where reimbursement timing and hospital procurement cycles can swing outcomes, that flexibility is non-trivial.
From an investor perspective, the absence of an explicit EPS figure or EPS consensus in this release means any evaluation of profitability versus expectations rests on the forthcoming 2026 guidance. The mention of a "revenue forecast" for 2026 implies management intends to set a more concrete path for earnings per share, even if we don’t yet see the numeric range. Keep an eye on the next quarterly update for a clearer read on whether the swing from revenue to EPS is achievable at the current cost structure.
What It Means for SGHT and Sector Peers
If the 2026 revenue forecast carries a sensible growth signal, Sight Sciences could begin to translate the current gross-margin resilience into a more meaningful path to operating leverage. The sector peers—other ophthalmic interventional device makers—will be watching whether SGHT can convert its improved cost structure into sustained top-line growth as reimbursement environments stabilize.
The emphasis on Interventional Glaucoma growth and Dry Eye reimbursement milestones suggests a multi-front strategy: push for procedural adoption, while anchoring revenue on payer-funded milestones. In a field where “earnings surprise” requires more than a one-quarter display of strength, a coherent 2026 plan paired with clear guidance could differentiate SGHT from slower-moving peers.
For investors tracking the narrative, the absence of immediate EPS data means the stock’s reaction will hinge on the clarity of the 2026 revenue forecast and the pace at which SGHT can translate that forecast into tangible earnings. In vanilla terms: the path from revenue to earnings may be less about a single leap and more about a careful climb, aided by cash discipline and market acceptance in core programs.
Data at a Glance
Company ticker: SGHT (Sight Sciences, Inc.). Earnings metrics such as EPS and EPS consensus are not disclosed in this release; the focus is on revenue, margins, operating expenses, and cash. Revenue forecast for 2026 is initiated but not numerically specified here. The material highlights a positive trajectory in high-margin components alongside disciplined cost control, set against a backdrop of ongoing reimbursement milestones in interventional ophthalmology.